Palivizumab: A Review of its Use as Prophylaxis for Serious Respiratory Syncytial Virus Infection

Author： Fenton Caroline   Scott Lesley J.   Plosker Greg L.  

Publisher： Adis International

ISSN： 1174-5878

Source： Pediatric Drugs, Vol.6, Iss.3, 2004-01, pp. : 177-197

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis

By Nuijten Mark J.C.   Wittenberg Wolfgang   Lebmeier Maximilian  

PharmacoEconomics, Vol. 25, Iss. 1, 2007-01 ,pp. : 55-71

Adis International

Access to resources Recommend Favorite

Evaluation of the Safety of Palivizumab in the Second Season of Exposure in Young Children at Risk for Severe Respiratory Syncytial Virus Infection

By Lacaze-Masmonteil T.  

Drug Safety, Vol. 26, Iss. 4, 2003-01 ,pp. : 283-291

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review

By PrescottJr William A.   Doloresco Fred   Brown Jack   Paladino Joseph A.  

PharmacoEconomics, Vol. 28, Iss. 4, 2010-04 ,pp. : 279-293

Adis International

Access to resources Recommend Favorite

Emerging drugs for respiratory syncytial virus infection

By Olszewska Wieslawa   Openshaw Peter  

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 2, 2009-06 ,pp. : 207-217

Informa Healthcare

Access to resources Recommend Favorite

Respiratory Syncytial Virus Infection in Elderly Adults

By Falsey Ann R.   Walsh Edward E.  

Drugs & Aging, Vol. 22, Iss. 7, 2005-01 ,pp. : 577-587

Adis International

Access to resources Recommend Favorite